Sponsored by:

Presented by:

Simultaneous detection of multiple gene mutations in non-small-cell lung cancer

Your details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)



If you’ve already registered, please click here to log in tothe webcast

Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene  (KRAS) are significant drivers in the development of non-small-cell lung cancer (NSCLC). Treatment is typically guided by which mutations are present, and there are several possible mutations that can arise during treatment, so detecting them quickly and reliably is key to helping the patient. 

With NSCLC, biopsied patient samples tend to be very small, which can hamper many conventional genetic tests. Thus the ideal test in NSCLC is one that can work with minimal inputs, and test for several mutations at the same time.

This webcast will present a new liquid biopsy test using multiplexing assays that contained mutant variants. The QX ONE Droplet Digital PCR (ddPCR) System allows for automated operation and advanced multiplexing to detect mutations in EGFR and KRAS using as little as 5 ng of cell-free DNA extracted from plasma.

The speaker will address:

  • What are the key benefits to having a high-throughput, multiplexing ddPCR system?
  • Are the results the same between standard duplex reactions and multiplexed reactions?
  • What is the greatest number of samples that can be processed to results overnight on the QX200 vs the QX ONE?
This webcast has been produced on behalf of the sponsor who retains sole responsibility for content. About this content.


Hestia Mellert, Ph.D.
Sr. Director, Development
Biodesix, Inc.
View Biography
Moderator: Sarah Hiddleston
Science Journalist
Nature Research for Nature Middle East
View Biography